Effective Use of Angiotensin II in Coronavirus Disease 19-Associated Mixed Shock State: A Case Report

Area of Science:

• Cardiology
• Infectious Diseases
• Pharmacology

Background:

• The COVID-19 pandemic necessitates novel therapeutic strategies.
• The virus's interaction with the ACE2 receptor highlights the renin-angiotensin system as a potential therapeutic target.
• Severe COVID-19 can lead to critical complications like acute respiratory distress syndrome (ARDS) and shock.

Observation:

• An elderly female patient with multiple comorbidities developed severe ARDS, cardiomyopathy, and vasodilatory shock due to COVID-19.
• The patient was treated with exogenous angiotensin II.
• Hemodynamic status was closely monitored following treatment.

Findings:

• The patient experienced rapid and significant hemodynamic improvement after angiotensin II administration.
• No adverse effects were observed during the treatment period.
• The treatment demonstrated a positive impact on the patient's critical condition.

Implications:

• Angiotensin II may be a potential therapeutic agent for managing vasodilatory shock in severe COVID-19.
• Further clinical investigation is warranted to confirm the efficacy and safety of angiotensin II in this context.
• This approach could offer a new treatment avenue for critical COVID-19 patients with shock.